- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05430906
AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecific Antibody) Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer: a Single-arm, Open-label, Multicenter Clinical Study
Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile.
AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to evaluate the efficacy and safety of AK104 combined with chemotherapy as the neoadjuvant treatment for advanced ovarian cancer.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jie Tang
- Phone Number: +8615274836636
- Email: tangjie@hnca.org.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Jie Tang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- 1. Woman ≥ 18 and ≤ 75 years old on day of signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 3. Advanced FIGO stage III to IV patient not able to receive primary debulking surgery for which neo adjuvant chemotherapy is recommended.
4. Have at least one measurable lesion per RECIST 1.1 assessed by investigator. 5. Have adequate organ function.
Key Exclusion Criteria:
1. Histological diagnosis of malignant tumor of non-epithelial origin of the ovary, the fallopian tube or peritoneum or borderline tumor of the ovary.
2. Patients with other active malignancies within 5 years prior to enrollment. 3. Known active autoimmune diseases. 4. Use of immunosuppressive agents within 14 days prior to the first dose of study treatment.
5. Presence of other uncontrolled serious medical conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AK104+chemotherapy
Participants received 3-4 neo-adjuvant cycles of AK104 10mg/kg Q3W then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] Q3W; followed by surgery
|
AK104 10mg/kg then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] of each 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete(R0) resection rate
Time Frame: Average 4 months after the start of drugs
|
The margin of the resected specimen showed no tumour involvement
|
Average 4 months after the start of drugs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: At the end of 3-4 cycles of neoadjuvant therapy (each cycle is 21 days)
|
The ORR is defined as the percentage of participants having complete response or partial response to protocol treatment.
Objective response will be measured by RECIST 1.1.
|
At the end of 3-4 cycles of neoadjuvant therapy (each cycle is 21 days)
|
|
Disease control rate (DCR)
Time Frame: At the end of 3-4 cycles of neoadjuvant therapy (each cycle is 21 days)
|
The DCR is defined as the proportion of subjects with complete response, partial response, or stable disease based on RECIST Version 1.1.
|
At the end of 3-4 cycles of neoadjuvant therapy (each cycle is 21 days)
|
|
Pathological Complete Response (pCR) Rate
Time Frame: One week after the surgery
|
The pCR is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.
|
One week after the surgery
|
|
Progression-free survival (PFS)
Time Frame: From the date of the start of drugs to date event, assessed up to 1 years
|
Progression-free survival is defined as the time from the start of drugs until the first documentation of disease progression or death due to any cause, whichever occurs first.
|
From the date of the start of drugs to date event, assessed up to 1 years
|
|
Number of participants with adverse events (AEs)
Time Frame: From the first dose of neoadjuvant treatment until 90 days after the last dose of neoadjuvant treatment
|
From the first dose of neoadjuvant treatment until 90 days after the last dose of neoadjuvant treatment
|
|
|
Number of participants with surgical complications
Time Frame: Intraoperatively, within 30 days after surgery
|
Intraoperatively, within 30 days after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jie Tang, Hunan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- AK104-IIT-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.